Intensified conditioning regimen in bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia
|
|
- Ami Warner
- 6 years ago
- Views:
Transcription
1 Bone Marrow Transplantation, (1998) 22, Stockton Press All rights reserved /98 $ Intensified conditioning regimen in bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia N Kröger 1, W Krüger 1, G Wacker-Backhaus 1, S Hegewisch-Becker 1, M Stockschläder 1, N Fuchs 1, BRüssmann 1, H Renges 1,MDürken 1, S Bielack 1, M de Wit 1, G Schuch 1, H Bartels 4, D Braumann 3, R Kuse 2, H Kabisch 1, R Erttmann 1 and AR Zander 1 1 Bone Marrow Transplantation Center and Department of Oncology/Hematology, University-Hospital Hamburg-Eppendorf; 2 Department of Hematology, Hospital St Georg, Hamburg; 3 Department of Hematology/Oncology, Hospital Altona, Hamburg; and 4 Department of Hematology, Community-Hospital, Lübeck, Germany Summary: We investigated an intensified conditioning regimen including fractionated total body irradiation (12 Gy), etoposide (30 45 mg/kg) and cyclophosphamide (120 mg/kg), followed by autologous (n = 5), allo-related (n = 13) or allo-unrelated (n = 6) bone marrow (n = 22) or peripheral stem cell (n = 2) transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. One patient received busulfan (16 mg/kg) instead of TBI. Nineteen patients were transplanted in 1CR, two in 2CR, one in 1PR and two in relapse. Major toxicity was mucositis grade II according to the Bearman scale in all patients. The treatmentrelated mortality was 25%, mainly due to infection or GVHD after allogeneic transplantation. After a median follow-up of 45 months (range 2 93), nine patients (37.5%) remain alive in CR. Nine patients (37.5%) relapsed and eight (33.3%) of these subsequently died. After autologous transplantation, four of five patients (80%) relapsed and died. Late relapse was seen after allogeneic, as well as autologous transplantation, at 33 and 59 months, respectively. The Kaplan Meier estimate of leukemia-free survival for all patients is 38% at 3 years (95% CI: 18 58%) and 35% at 5 years (95% CI: 15 55%). For allogeneic transplants in first CR (n = 15) the estimate of disease-free survival was 46% at 3 years (95% CI: 19 73%) and 34% at 5 years (95% CI: 17 51%). Patients aged below 30 years had a better estimated overall survival at 3 years (61% vs 11%, P 01). The bcr-abl fusion transcript (p210 vs p190 vs p210/190) did not affect disease-free or overall survival. In our experience, an intensified conditioning regimen seems to improve the results of bone marrow transplantation in patients with Ph acute lymphoblastic leukemia. However, the high relapse rate warrants novel approaches to enhance anti-leukemic efficacy. Keywords: bone marrow transplantation; total body irradiation; etoposide; Philadelphia chromosome-positive acute lymphoblastic leukemia Correspondence: Dr N Kröger, Bone Marrow Transplantation Center, University Hospital Hamburg-Eppendorf, Martinistrasse 52, D Hamburg, Germany Received 27 April 1998; accepted 19 July 1998 The Philadelphia chromosome is detectable in 2 to 6% of children and in approximately 25% of adults with acute lymphoblastic leukemia. 1,2 Despite the high remission rate (57 96%) seen with intensified conventional combination chemotherapy, almost all patients relapse, resulting in a dismal long-term prognosis. 3 5 Autologous and allogeneic bone marrow transplantation may cure a proportion of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia The International Bone Marrow Transplant Registry reported a 31% leukemia-free survival after allogeneic transplantation from HLA-identical siblings at 2 years for all patients, and of 38% for patients transplanted in first remission. 8 After autologous transplantation approximately 70% of patients relapse. 12,13 Therefore, new approaches to reduce the relapse rate are needed. We investigated an intensified conditioning regimen with total body irradiation (12 Gy) or busulfan (16 mg/kg), etoposide (30 45 mg/kg) and cyclophosphamide (120 mg/kg) in 24 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. After promising results from an interim analysis of the first 14 patients, 11 we now report the results of 24 patients, with a median follow-up of 45 months. Patients and methods Between August 1990 and November 1997, 24 patients with a median age of 28.5 years (range: 2 60) and cytogenetically proven Philadelphia chromosome-positive acute lymphoblastic leukemia were treated with an intensified conditioning regimen followed by allogeneic or autologous bone marrow transplantation. Twenty-three patients received TBI, etoposide and cyclophosphamide and one patient received busulfan (16 mg/kg), etoposide and cyclophosphamide. The conditioning regimen is given in Table 1. Table 1 Intensified conditioning regimen Total body irradiation 2 2 Gy day 7, 6, 5 Etoposide mg/kg day 4 Cyclophosphamide 60 mg/kg day 3, 2 Bone marrow/pbsc day 0
2 1030 Table 2 Patient characteristics Patient Age Disease Stem cell source bcr-abl VP16-dose Acute GVHD Relapse Survival Cause of death (sex) (years) status transcript (mg/kg) grade (months) (months) 1 (F) 43 1CR autobm p Y (18) 2 relapse 2 (F) 48 1CR autobm NA 45 Y (4) 6.8 relapse 3 (M) 6 1CR autobm p N (M) 23 1CR autobm p Y (4) 21.8 relapse 5 (F) 24 2CR autobm p Y (59) 65.9 relapse 6 (M) 18 1CR allobm p N (M) 60 1CR allopbsc NA 30 0 N 5.4 graft-failure/sepsis 8 (M) 21 1CR allobm NA 45 0 N (F) 30 1CR allobm p Y (3) 19.4 relapse 10 (M) 36 1CR allobm p N 8.9 interst pneumonia 11 (M) 32 1CR allobm p Y (33) 49.9 relapse 12 (M) 39 1 Relapse allobm NA 45 3 N 0.7 sepsis 13 (F) 4 1CR allobm p Y (6) 1 14 (M) 22 1CR allobm p N (F) 31 1CR allopbsc p N 17.8 TTP/CMV 16 (F) 28 1CR allobm p N (F) 29 2 Relapse allobm p N 8.1 cerebral bleeding/gvhd 18 (M) 45 2CR allobm p Y (5) 21.6 relapse 19 (F) 2 1CR allobm (MUD) p210/ N (F) 18 1CR allobm (MUD) p N (M) 38 1CR allobm (MUD) p210/ N 3.0 CMV 22 (M) 7 1CR allobm (MUD) p Y (9) 25.2 relapse 23 (M) 45 1PR allobm (MUD) NA 45 1 N (M) 14 1CR allobm (MUD) p N 20.5 CR = complete remission; PR = partial remission; Y = yes; N = no; NA = not applicable. Thirteen patients were transplanted with HLA-identical (including two minor mismatches) bone marrow (n = 11) or peripheral blood progenitor cells (n = 2); six patients were transplanted with HLA-identical bone marrow from an unrelated donor and five patients received autologous bone marrow which was purged in two patients (one by mafosfamide; one by immunological means). One of these patients experienced delayed engraftment after mafosfamide purged bone marrow transplantation and received additional unpurged back-up marrow. For allogeneic bone marrow transplantation, graft-versus-host (GVHD) prophylaxis consisted of cyclosporin A and methotrexate in all patients and anti-thymocyte globulin (ATG) in 10 patients. Acute and chronic GVHD were diagnosed and graded according to the standard criteria. 14 Acute GVHD was treated with methylprednisolone and/or anti-thymocyte globulin. Nineteen patients were studied for both p210 bcr-abl and p190 bcr-abl fusion transcript in marrow before induction chemotherapy as described elsewhere. 11 Nineteen patients were transplanted in first complete remission, two in second complete remission, one in first partial remission and two in relapse. Treatment-related toxicities were classified according to the Bearman scale. 15 The median time from diagnosis to BMT was 5.5 months (range 3 14). Two relapsed patients who received a second transplant (cord blood and allogeneic PBSC) died of treatment-related complications (infections/gvhd). Patient characteristics are listed in Table 2. Statistic analysis was performed using WinSTAT software (Kalmia, Cambridge, MA, USA). Disease-free (DFS) and overall survival (OS) were calculated by the methods of Kaplan and Meier. 16 The log rank test was used for comparison. A P value of 5 was considered significant. Results Engraftment and toxicity The median time to reach leukocytes /nl was 18 days (range 12 25). One patient died of early infection (day 21) and one patient did not engraft sufficiently after mafosfamide purged autologous marrow and received a marrow boost of unpurged back-up marrow. One allogeneic patient did not engraft and died of infection. The median time for platelets 20/nl was 28 days (range 16 39) for 19 evaluable patients. Mean toxicity of the intensified conditioning regimen was mucositis grade II in all patients requiring intravenous morphine. Hepatic and skin toxicities were slightly higher in the 45 mg/kg than in the 30 mg/kg group (Table 3). Nine of 19 (47%) patients in the allogeneic group developed grade II/III acute GVHD. Chronic GVHD developed in three patients (15%). Overall, six patients (25%) died of causes other than leukemia after allogeneic Table 3 Toxicity of TBI, cyclophosphamide and etoposide regimen related to etoposide (VP16) dose Toxicity VP16 30 mg/kg VP16 45 mg/kg (n = 9) (n = 15) Mucositis a II 100% 100% Liver a I 44% 46% II 13% GI tract a I 22% Renal a I 22% 26% Skin: erythema 11% 46% a According to the Bearman score. 15
3 transplantation (graft-failure/sepsis, n = 1; CMV pneumonia, n = 1; cerebral bleeding/gvhd, n = 1; TTP, n = 1; interstitial pneumonia, n = 1; Candida crusei sepsis, n = 1), whereas no deaths occurred after autologous transplantation. Survival and relapse After a median follow-up of 45 months (range 2 93), nine patients (37.5%) remain alive in CR. Nine patients (37.5%) relapsed and eight (33.3%) of these subsequently died. The Kaplan Meier estimate of leukemia-free survival for all patients is 38% at 3 years (95% CI: 18 58%) and 35% at 5 years (95% CI: 15 55%) (Figure 1). Four of five patients (80%) relapsed after autologous transplantation and subsequently died. For all patients neither hematologic status (1CR vs 1CR) at BMT, type of transplant (autologous vs allogeneic), nor etoposide dose (30 mg vs 45 mg/kg) affected outcome. Six of nine relapses occurred within the first year after transplantation. However, late relapse was seen in three patients at 18, 33 and 59 months after autologous or allogeneic transplantation. The bcr-abl fusion transcript (p210 vs p190 vs p210/190) did not affect disease-free or overall survival (P = 0.74). For allogeneic transplants in first CR (n = 15) the estimate of disease-free and overall survival was 46% (95% CI: 19 73%) and 50% at 3 years and 34% (95% CI: 17 51%) and 38% at 5 years. In this subgroup, transplantation in first CR resulted in a better disease-free and overall survival compared to transplantation beyond first remission (P = 5 and P = 38) (Figure 2). Age at time of bone marrow transplantation significantly affected outcome. The estimated overall survival at 3 years was 62% for patients less than 30 years and only 11% for patients 30 years (P 01) (Figure 3). Discussion In the largest series of 67 bone marrow transplants from HLA-identical siblings for Philadelphia chromosome-posi- n = 24 DFS (months) Figure 1 Disease-free survival after autologous or allogeneic bone marrow transplantation in 24 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. n = 4 n = 15 Remission 1CR >1CR P = 4 Overall survival (months) Figure 2 Overall survival after allogeneic bone marrow transplantation in 1CR (n = 15) or beyond first remission status (n = 4) in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. n = 14 n = 10 P < 01 Age <30 >30 Overall survival (months) Figure 3 Overall survival according to age at time of autologous or allogeneic bone marrow transplantation in 24 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. tive acute lymphoblastic leukemia, the International Bone Marrow Transplant Registry reported a 31% leukemia-free survival at 2 years for all patients and 38% for patients transplanted in first remission. 8 Less extensive studies with a short follow-up have reported similar results. Forman et al 6 reported that six of 10 patients were alive after allogeneic bone marrow transplantation and a median followup of 19 months. Miryamura et al 7 reported seven of 15 patients who were transplanted for Ph acute lymphoblastic leukemia and who were disease-free after a median follow-up of 21 months. However, the results of studies with a longer follow-up are significantly worse. Arnold et al 10 reported 19 patients with Ph acute lymphoblastic leukemia undergoing autologous or allogeneic bone marrow transplantation who had a 22% probability of being diseasefree at 5 years. The results from Dunlop et al 17 are even worse. The estimated overall survival for 19 patients is 37.5% at 3 years and only 12.5% at 5 years, with no differences in outcome between autologous and allogeneic transplantation. The high probability of relapse is the major fac- 1031
4 1032 tor for poor outcome. Our approach to reducing relapse rate after transplantation was to use an intensified conditioning regimen prior to bone marrow transplantation. The results of this intensified conditioning regimen including total body irradiation, etoposide and cyclophosphamide appear to be more effective, with 38% probability of leukemiafree survival at 3 years and 35% at 5 years for all patients. The best results were seen after allogeneic transplantation in first CR, with an estimated disease-free survival of 46% at 3 years and 34% at 5 years. However, even after a median follow-up of 45 months, patients with long-term disease-free survival cannot be considered as cured, since late relapses occurred in our study up to 33 months after allogeneic and up to 59 months after autologous transplantation. Similar results for allogeneic transplantation with genotypically identical sibling donors in first CR have been recently reported by Chao et al. 9 After conditioning with fractionated TBI either with cyclophosphamide and/or etoposide, a 46% probability of disease-free state at 4 years for this group of patients was reported. The effectiveness of an intensified conditioning regimen including etoposide and TBI in advanced leukemia has been reported earlier. 18,19 The main toxicity of the conditioning regimen has been mucositis in all patients, requiring intravenous analgesics. Hepatic toxicity was slightly higher in the 45 mg/kg group and skin toxicity was usually mild and reversible. Treatment-related mortality was 25% and occurred only in allogeneic transplants mainly due to infections and GVHD. Age has had a significant impact on outcome in our study. 62% of patients transplanted at under 30 years of age and only 11% of the patients transplanted after the age of 30 years are projected to be alive at 3 years (P 01). Patients bearing the p210 bcr-abl may have a better outcome after conventional chemotherapy than patients bearing the p190 transcript, and type of bcr-abl chimeric mrna post-transplant correlates with relapse. 4,20,21 We found no correlation between the type of bcr-abl transcript and outcome after BMT. Four of five patients transplanted with purged or unpurged autologous marrow relapsed and subsequently died. Because of the small number of patients and lack of treatment-related deaths after autologous transplantation, there was no difference between the type of transplant (autologous vs allogeneic). Unrelated donor marrow transplantation seems to be an alternative treatment for young patients who lack a family donor. In 18 patients who underwent unrelated bone marrow transplantation, a 49% probability of leukemia-free survival at 2 years has been reported. 22 Our study confirmed the feasibility of unrelated donor transplantation in six patients with no difference in outcome compared with 13 patients transplanted from family donors. A graft-versus-leukemia effect might decrease relapse rates in allograft patients. Because of small numbers and the low incidence of severe GVHD, the impact of GVHD/GVL on outcome cannot be determined. Attempts to reduce hematological relapse have been made successfully by donor leukocyte infusion. 23 Our results suggest that intensified conditioning therapy with TBI, etoposide and cyclophosphamide may improve the results of bone marrow transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia, with acceptable toxicity. Allogeneic transplantation in first complete remission is likely to result in the best outcome. In young patients who lack a family donor an unrelated donor search should be performed early. However, because of the high relapse rate post-transplant investigational approaches are warranted to reduce relapse rate and improve results after allogeneic bone marrow transplantation. Acknowledgements We thank the staff of the BMT unit for providing excellent care for our patients and the medical technicians for their excellent work in the BMT laboratory. References 1 Hoelzer D. Treatment of acute lymphoblastic leukemia. Semin Hematol 1994; 31: Lestingi T, Hooberman A. Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematol Oncol Clin N Am 1993; 7: Bloomfield CD, Goldman AI, Alimena G et al. Chromosomal abnormalities identify high-risk and low-risk patients with acute lymphoblastic leukemia. Blood 1986; 67: Kantarjian HM, Talpaz M, Dhingra K et al. Significance of P210 versus P190 molecular abnormalities in adults with Philadelphia positive acute lymphoblastic leukemia. Blood 1991; 78: Fletcher JA, Lynch EA, Kimball VM et al. Translocation (9;22) is associated with extremely poor prognosis in intensively treated children with acute lymphoblastic leukemia. Blood 1991; 77: Forman SJ, O Donnell MR, Nademanee AP et al. Bone marrow transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1987; 70: Miyamura K, Tanimoto M, Morishima Y et al. Detection of Philadelphia chromosome-positive acute lymphoblastic leukemia by polymerase chain reaction: possible eradication of minimal residual disease by bone marrow transplantation. Blood 1992; 79: Barret AJ, Horowitz MM, Ash RC et al. Bone marrow transplantation leukemia. Blood 1992; 79: Chao NJ, Blume KJ, Forman SJ et al. Long-term follow-up of allogeneic bone marrow recipients for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1995; 85: Arnold R, Heyll A, Kolb JH et al. Bone marrow transplantation leukemia after intensified chemotherapy according the German multicentre studies for ALL. Bone Marrow Transplant 1995; 15 (Suppl. 2): S71 (Abstr). 11 Stockschläder M, Hegewisch-Becker S, Krüger W et al. Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant 1995; 16: Annino L, Ferrari A, Cedrone M et al. Adult Philadelphia chromosome-positive acute lymphoblastic leukemia: experience of treatments during a 10-year period. Leukemia 1994; 8: Powles R, Mehta J, Singhal S et al. Autologous bone marrow or peripheral blood stem cell transplantation followed by maintenance chemotherapy for adult acute lymphoblastic leu-
5 kemia in first remission: 50 cases from a single center. Bone Marrow Transplant 1995; 16: Prepiorka D, Weisdorf D, Martin P et al consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: Bearman SI, Appelbaum FR, Buckner CD et al. Regimenrelated toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: Dunlop LC, Powles R, Singhal S et al. Bone marrow transplantation leukemia. Bone Marrow Transplant 1996; 17: Blume K, Forman S, O Donnell MR et al. Total body irradiation and high dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematological malignancies. Blood 1987; 69: Schmitz N, Gassmann W, Rister M et al. Total body irradiation and high-dose VP followed by allogeneic bone marrow transplantation in advanced leukemias. Blood 1988; 72: Radich J, Kopecky K, Boldt D et al. Detection of bcr-abl fusion genes in adult acute lymphoblastic leukemia by polymerase chain reaction. Leukemia 1994; 8: Radich J, Gehly G, Lee A et al. Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation. Blood 1997; 7: Sierra J, Radich J, Hansen JA et al. Marrow transplants from unrelated donors for treatment of Philadelphia chromosomepositive acute lymphoblastic leukemia. Blood 1997; 4: Yazaki M, Andoh M, Ito T et al. Successful prevention of hematological relapse for patient with Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic bone marrow transplantation by donor leukocyte infusion. Bone Marrow Transplant 1997; 19:
5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow
5/9/2018 or Stem Cell Harvest Where we are now, and What s Coming AA MDS International Foundation Indianapolis IN Luke Akard MD May 19, 2018 Infusion Transplant Conditioning Treatment 2-7 days STEM CELL
More informationReduced-intensity Conditioning Transplantation
Reduced-intensity Conditioning Transplantation Current Role and Future Prospect He Huang M.D., Ph.D. Bone Marrow Transplantation Center The First Affiliated Hospital Zhejiang University School of Medicine,
More informationHLA-DR-matched Parental Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-risk Acute Leukemia
BRIEF COMMUNICATION HLA-DR-matched Parental Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-risk Acute Leukemia Shang-Ju Wu, Ming Yao,* Jih-Luh Tang, Bo-Sheng Ko, Hwei-Fang
More informationALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOBLASTIC LEUKEMIAS
ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOBLASTIC LEUKEMIAS Didier Blaise, MD Transplant and Cellular Therapy Unit (U2T) Department of Hematology Centre de Recherche en Cancérologie, Inserm U891
More informationHematopoietic Stem Cell Transplantation for Patients with Chronic Myeloid Leukemia
398 Hematopoietic Stem Cell Transplantation for Patients with Chronic Myeloid Leukemia Qifa Uu Zhiping Fan Jing Sun Yu Zhang Xiaoli Uu Dan Xu Bing Xu Ru Feng Fanyi Meng Shuyun Zhou Department of Hematology,
More informationKT Godder, J Metha, KY Chiang, S Adams, F van Rhee, S Singhal, K Higgins-Smith, W O Neal, S DeRienzo and JP Henslee-Downey.
(2001) 28, 1031 1036 2001 Nature Publishing Group All rights reserved 0268 3369/01 $15.00 www.nature.com/bmt Acute myeloid leukaemia Partially mismatched related donor bone marrow transplantation as salvage
More informationWhat s a Transplant? What s not?
What s a Transplant? What s not? How to report the difference? Daniel Weisdorf MD University of Minnesota Anti-cancer effects of BMT or PBSCT [HSCT] Kill the cancer Save the patient Restore immunocompetence
More informationTrends in Hematopoietic Cell Transplantation. AAMAC Patient Education Day Oct 2014
Trends in Hematopoietic Cell Transplantation AAMAC Patient Education Day Oct 2014 Objectives Review the principles behind allogeneic stem cell transplantation Outline the process of transplant, some of
More information3.1 Clinical safety of chimeric or humanized anti-cd25 (ch/anti-cd25)
3 Results 3.1 Clinical safety of chimeric or humanized anti-cd25 (ch/anti-cd25) Five infusions of monoclonal IL-2 receptor antibody (anti-cd25) were planned according to protocol between day 0 and day
More informationUse of a five-agent GVHD prevention regimen in recipients of unrelated donor marrow
Bone Marrow Transplantation, (1999) 23, 889 893 1999 Stockton Press All rights reserved 0268 3369/99 $12.00 http://www.stockton-press.co.uk/bmt Use of a five-agent GVHD prevention regimen in recipients
More informationAn Overview of Blood and Marrow Transplantation
An Overview of Blood and Marrow Transplantation October 24, 2009 Stephen Couban Department of Medicine Dalhousie University Objectives What are the types of blood and marrow transplantation? Who may benefit
More informationFeasibility and Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in 30 Patients with Poor Risk Acute Myeloid Leukemia Older than 60 Years
The Open Leukemia Journal, 2010, 3, 55-59 55 Open Access Feasibility and Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in 30 Patients with Poor Risk Acute Myeloid Leukemia Older than Years
More informationHaploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017
Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017 Allogeneic Transplant Recipients in the US, by Donor Type 9000
More informationMUD SCT. Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University
MUD SCT Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University Outlines Optimal match criteria for unrelated adult donors Role of ATG in MUD-SCT Post-transplant
More informationMyeloablative and Reduced Intensity Conditioning for HSCT Annalisa Ruggeri, MD, Hôpital Saint Antoine Eurocord- Hôpital Saint Louis, Paris
Myeloablative and Reduced Intensity Conditioning for HSCT Annalisa Ruggeri, MD, Hôpital Saint Antoine Eurocord- Hôpital Saint Louis, Paris 18th ESH - EBMT Training Course on HSCT 8-10 May 2014, Vienna,
More informationIntroduction to Clinical Hematopoietic Cell Transplantation (HCT) George Chen, MD Thursday, May 03, 2018
Introduction to Clinical Hematopoietic Cell Transplantation (HCT) George Chen, MD Thursday, May 03, 2018 The transfer of hematopoietic progenitor and stem cells for therapeutic purposes Hematopoietic Cell
More informationHaploidentical Transplantation today: and the alternatives
Haploidentical Transplantation today: and the alternatives Daniel Weisdorf MD University of Minnesota February, 2013 No matched sib: where to look? URD donor requires close HLA matching and 3-12 weeks
More informationKEY WORDS. Acute lymphoblastic leukemia Etoposide Cyclophosphamide Total body irradiation Conditioning regimen Sibling allografts
Biology of Blood and Marrow Transplantation 12:438-453 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1204-0007$32.00/0 doi:10.1016/j.bbmt.2005.12.029 A Comparison of Cyclophosphamide
More informationBone Marrow Transplantation in Myelodysplastic Syndromes. An overview for the Myelodysplasia Support Group of Ottawa
Bone Marrow Transplantation in Myelodysplastic Syndromes An overview for the Myelodysplasia Support Group of Ottawa Objectives Provide brief review of marrow failure Re emphasize the importance of predictions
More informationExperience of patients transplanted with naïve T cell depleted stem cell graft in CMUH
Experience of patients transplanted with naïve T cell depleted stem cell graft in CMUH Tzu-Ting Chen, Wen-Jyi Lo, Chiao-Lin Lin, Ching-Chan Lin, Li-Yuan Bai, Supeng Yeh, Chang-Fang Chiu Hematology and
More informationAutologous versus Allogeneic Unrelated Donor Transplantation for Acute Lymphoblastic Leukemia: Comparative Toxicity and Outcomes
Biology of Blood and Marrow Transplantation 8:213-220 (2002) 2002 American Society for Blood and Marrow Transplantation ASBMT Autologous versus Allogeneic Unrelated Donor Transplantation for Acute Lymphoblastic
More informationA CLINICAL STUDY OF THE HEMATOPOIETIC STEM CELL TRANSPLANTATION IN 112 PATIENTS WITH LEUKEMIA AND OTHER MALIGNANT DISEASES
Chinese Journal of Cancer Research 9(1):36--40,1997, Clinical Observations A CLINICAL STUDY OF THE HEMATOPOIETIC STEM CELL TRANSPLANTATION IN 112 PATIENTS WITH LEUKEMIA AND OTHER MALIGNANT DISEASES Liu
More informationMUD HSCT as first line Treatment in Idiopathic SAA. Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK
MUD HSCT as first line Treatment in Idiopathic SAA Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK No Financial Disclosures Guidelines for management of aplastic anaemia British
More informationAn Introduction to Bone Marrow Transplant
Introduction to Blood Cancers An Introduction to Bone Marrow Transplant Rushang Patel, MD, PhD, FACP Florida Hospital Medical Group S My RBC Plt Gran Polycythemia Vera Essential Thrombocythemia AML, CML,
More informationRob Wynn RMCH & University of Manchester, UK. HCT in Children
Rob Wynn RMCH & University of Manchester, UK HCT in Children Summary Indications for HCT in children Donor selection for Paediatric HCT Using cords Achieving engraftment in HCT Conditioning Immune action
More informationEBMT2008_22_44:EBMT :29 Pagina 454 CHAPTER 30. HSCT for Hodgkin s lymphoma in adults. A. Sureda
EBMT2008_22_44:EBMT2008 6-11-2008 9:29 Pagina 454 * CHAPTER 30 HSCT for Hodgkin s lymphoma in adults A. Sureda EBMT2008_22_44:EBMT2008 6-11-2008 9:29 Pagina 455 CHAPTER 30 HL in adults 1. Introduction
More informationKEY WORDS: Allogeneic, Hematopoietic cell transplantation, Graft-versus-host disease, Immunosuppressants, Cyclosporine, Tacrolimus
A Retrospective Comparison of Tacrolimus versus Cyclosporine with Methotrexate for Immunosuppression after Allogeneic Hematopoietic Cell Transplantation with Mobilized Blood Cells Yoshihiro Inamoto, 1
More informationStem Cell Transplantation for Severe Aplastic Anemia
Number of Transplants 10/24/2011 Stem Cell Transplantation for Severe Aplastic Anemia Claudio Anasetti, MD Professor of Oncology and Medicine Chair, Blood and Marrow Transplant Dpt Moffitt Cancer Center
More informationHematology and Oncology, The Cleveland Clinic, Cleveland, Ohio; 3 Department of Biostatistics, The Ohio State University Hospitals, Columbus, Ohio
Biology of Blood and Marrow Transplantation 12:61-67 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1201-0004$32.00/0 doi:10.1016/j.bbmt.2005.06.004 High Disease Burden
More informationKEY WORDS: CRp, Platelet recovery, AML, MDS, Transplant
Platelet Recovery Before Allogeneic Stem Cell Transplantation Predicts Posttransplantation Outcomes in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndrome Gheath Alatrash, Matteo Pelosini,
More informationTHE ROLE OF TBI IN STEM CELL TRANSPLANTATION. Dr. Biju George Professor Department of Haematology CMC Vellore
THE ROLE OF TBI IN STEM CELL TRANSPLANTATION Dr. Biju George Professor Department of Haematology CMC Vellore Introduction Radiotherapy is the medical use of ionising radiation. TBI or Total Body Irradiation
More informationAllogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD
Allogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD Overview: Update on allogeneic transplantation for malignant and nonmalignant diseases: state
More informationHematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia
Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia Policy Number: 8.01.32 Last Review: 7/2018 Origination: 7/2002 Next Review: 7/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue
More informationAbstract 861. Stein AS, Topp MS, Kantarjian H, Gökbuget N, Bargou R, Litzow M, Rambaldi A, Ribera J-M, Zhang A, Zimmerman Z, Forman SJ
Treatment with Anti-CD19 BiTE Blinatumomab in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R ALL) Post-Allogeneic Hematopoietic Stem Cell Transplantation Abstract
More informationBone Marrow Transplantation and the Potential Role of Iomab-B
Bone Marrow Transplantation and the Potential Role of Iomab-B Hillard M. Lazarus, MD, FACP Professor of Medicine, Director of Novel Cell Therapy Case Western Reserve University 1 Hematopoietic Cell Transplantation
More informationA.M.W. van Marion. H.M. Lokhorst. N.W.C.J. van de Donk. J.G. van den Tweel. Histopathology 2002, 41 (suppl 2):77-92 (modified)
chapter 4 The significance of monoclonal plasma cells in the bone marrow biopsies of patients with multiple myeloma following allogeneic or autologous stem cell transplantation A.M.W. van Marion H.M. Lokhorst
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationBB&MT. KEY WORDS Acute lymphoblastic leukemia Hematopoietic stem cell transplantation Therapy Adult
Biology of Blood and Marrow Transplantation 12:1-30 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1201-0001$32.00/0 doi:10.1016/j.bbmt.2005.10.018 The Role of Cytotoxic
More informationHaploidentical Stem Cell Transplantation with post transplantation Cyclophosphamide for the treatment of Fanconi Anemia
Haploidentical Stem Cell Transplantation with post transplantation Cyclophosphamide for the treatment of Fanconi Anemia Carmem Bonfim Director Pediatric Blood and Marrow Transplantation Program HC Federal
More informationAIH, Marseille 30/09/06
ALLOGENEIC STEM CELL TRANSPLANTATION FOR MYELOID MALIGNANCIES Transplant and Cellular Therapy Unit Institut Paoli Calmettes Inserm U599 Université de la Méditerranée ée Marseille, France AIH, Marseille
More informationMedical Policy. MP Hematopoietic Cell Transplantation for Acute Myeloid Leukemia
Medical Policy MP 8.01.26 BCBSA Ref. Policy: 8.01.26 Last Review: 01/30/2018 Effective Date: 01/30/2018 Section: Therapy Related Policies 2.04.124 Genetic Testing for FLT3, NPM1, and CEBPA Variants in
More informationEBMT Complications and Quality of Life Working Party Educational Course
EBMT Complications and Quality of Life Working Party Educational Course Organisers: R. Duarte, G. Basak 23-24 October 2014, Warsaw, Poland #EBMT2014 www.ebmt.org EBMT Complications and Quality of Life
More informationOutcome of acute leukemia patients with central nervous system (CNS) involvement treated with total body or CNS irradiation before transplantation
Original Article Page 1 of 9 Outcome of acute leukemia patients with central nervous system (CNS) involvement treated with total body or CNS irradiation before transplantation Wen-Han Kuo 1, Yu-Hsuan Chen
More informationNon-Myeloablative Transplantation
Non-Myeloablative Transplantation David G. Maloney, Brenda M. Sandmaier, Stephen Mackinnon, and Judith A. Shizuru The concept of utilizing enhanced immunosuppression rather than myeloablative cytotoxic
More informationNeutrophil Recovery: The. Posttransplant Recovery. Bus11_1.ppt
Neutrophil Recovery: The First Step in Posttransplant Recovery No conflicts of interest to disclose Bus11_1.ppt Blood is Made in the Bone Marrow Blood Stem Cell Pre-B White cells B Lymphocyte T Lymphocyte
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_cell_transplantation_for_cll_and_sll 2/2001
More informationJPMA ( Journal Of Pakistan Medical Association) Vol 53, No.9,Sep Original Articles
JPMA ( Journal Of Pakistan Medical Association) Vol 53, No.9,Sep. 2003 Original Articles Outcome of Adult Acute Lymphoblastic Leukemia: a Single Center Experience M. Usman, I. Burney*, A. Nasim*, S. N.
More informationAcute myeloid leukemia: prognosis and treatment. Dimitri A. Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Campus Stuivenberg
Acute myeloid leukemia: prognosis and treatment Dimitri A. Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Campus Stuivenberg Patient Female, 39 years History: hypothyroidism Present:
More informationIl Trapianto da donatore MUD. Alessandro Rambaldi
Il Trapianto da donatore MUD Alessandro Rambaldi Overview Comparison of outcomes of allo- HSCT from matched related and unrelated donors. We need evidence based results! Is the Dme needed to find an unrelated
More informationUKALL14. Non-Myeloablative Conditioning Regimen (1/1) Date started (dd/mm/yyyy) (Day 7) Weight (kg) BSA (m 2 )
Non-Myeloablative Conditioning Regimen (1/1) started (dd/mm/yyyy) (Day 7) BSA (m 2 ) Weight (kg) Please enter the daily dose given in the table below: Day Fludarabine (mg) Melphalan (mg) Alemtuzumab (mg)
More informationM Cavo, G Bandini, M Benni, A Gozzetti, S Ronconi, G Rosti, E Zamagni, RM Lemoli, A Bonini, A Belardinelli, MR Motta, S Rizzi and S Tura
Bone Marrow Transplantation, (1998) 22, 27 32 1998 Stockton Press All rights reserved 268 3369/98 $12. http://www.stockton-press.co.uk/bmt High-dose busulfan and cyclophosphamide are an effective conditioning
More informationFederica Galaverna, 1 Daria Pagliara, 1 Deepa Manwani, 2 Rajni Agarwal-Hashmi, 3 Melissa Aldinger, 4 Franco Locatelli 1
Administration of Rivogenlecleucel (Rivo-cel, BPX-501) Following αβ T- and B-Cell Depleted Haplo-HSCT in Children With Transfusion-Dependent Thalassemia Federica Galaverna, 1 Daria Pagliara, 1 Deepa Manwani,
More informationBack to the Future: The Resurgence of Bone Marrow??
Back to the Future: The Resurgence of Bone Marrow?? Thomas Spitzer, MD Director. Bone Marrow Transplant Program Massachusetts General Hospital Professor of Medicine, Harvard Medical School Bone Marrow
More informationCIBMTR Center Number: CIBMTR Recipient ID: Today s Date: Date of HSCT for which this form is being completed:
Chronic Myelogenous Leukemia (CML) Post-HSCT Data Sequence Number: Date Received: Registry Use Only Today s Date: Date of HSCT for which this form is being completed: HSCT type: autologous allogeneic,
More informationHematopoietic Cell Transplantation for Myelofibrosis. Outline
Hematopoietic Cell Transplantation for Myelofibrosis H.Joachim Deeg MD Fred Hutchinson Cancer Research Center & University of Washington, Seattle WA Great Debates, NY, 4/28/2012 Outline Rationale for hematopoietic
More informationImmunosuppressive Therapy and Bone Marrow Transplantation for Aplastic Anaemia The CMC Experience
36 supplement to Journal of the association of physicians of india Published on 1st of every month 1st march, 2015 Immunosuppressive Therapy and Bone Marrow Transplantation for Aplastic Anaemia The CMC
More informationIntroduction to Hematopoietic Stem Cell Transplantation
Faculty Disclosures Introduction to Hematopoietic Stem Cell Transplantation Nothing to disclose Jeanne McCarthy-Kaiser, PharmD, BCOP Clinical Pharmacist, Autologous Stem Cell Transplant/Long- Term Follow-Up
More informationHematopoietic Stem Cell Transplant in Sickle Cell Disease- An update
Hematopoietic Stem Cell Transplant in Sickle Cell Disease- An update Dr Chirag A Shah Diplomate American Board of Hematology and Medical Oncology Director, Dept of Hemato-Oncology and Stem Cell Transplant
More informationUmbilical Cord Blood Transplantation
Umbilical Cord Blood Transplantation Current Results John E. Wagner, M.D. Blood and Marrow Transplant Program and Stem Cell Institute University of Minnesota Donor Choices Unrelated Marrow/PBSC Results
More informationDedicated to Gordon. Stem Cell Transplantation: The Journey
Dedicated to Gordon Stem Cell Transplantation: The Journey 1949 Jacobson et al: Radioprotection by lead shielding of the spleen of a lethally irradiated animal 1951 Lorenz et al: Radiation protection
More informationHaplo vs Cord vs URD Debate
3rd Annual ASBMT Regional Conference for NPs, PAs and Fellows Haplo vs Cord vs URD Debate Claudio G. Brunstein Associate Professor University of Minnesota Medical School Take home message Finding a donor
More informationMedical Benefit Effective Date: 07/01/12 Next Review Date: 03/13 Preauthorization* Yes Review Dates: 04/07, 05/08, 03/10, 03/11, 03/12
Hematopoietic Stem-Cell Transplantation for Chronic Myelogenous (80130) Medical Benefit Effective Date: 07/01/12 Next Review Date: 03/13 Preauthorization* Yes Review Dates: 04/07, 05/08, 03/10, 03/11,
More informationPoor Outcome in Steroid-Refractory Graft-Versus-Host Disease With Antithymocyte Globulin Treatment
Biology of Blood and Marrow Transplantation 8:155-160 (2002) 2002 American Society for Blood and Marrow Transplantation ASBMT Poor Outcome in Steroid-Refractory Graft-Versus-Host Disease With Antithymocyte
More informationLe infezioni fungine nel trapianto di cellule staminali emopoietiche. Claudio Viscoli Professor of Infectious Disease University of Genova, Italy
Le infezioni fungine nel trapianto di cellule staminali emopoietiche Claudio Viscoli Professor of Infectious Disease University of Genova, Italy Potential conflicts of interest Received grants as speaker/moderator
More informationAcute Lymphoblastic and Myeloid Leukemia
Acute Lymphoblastic and Myeloid Leukemia Pre- and Post-Disease Form Acute Lympoblastic Leukemia Mary Eapen MD, MS Acute Lymphoblastic Leukemia SEER Age-adjusted incidence rate 1.6 per 100,000 men and women
More informationSummary of Changes BMT CTN 1101 Version 7.0 to 8.0 Dated: January 18, Original text: Changed to: Rationale
BMT CTN 1101 RIC ducb vs. Haplo Page 1 of 10 Date: January 20, 2017 Summary of Changes BMT CTN 1101 Version 7.0 to 8.0 Dated: January 18, 2017 A Multi-Center, Phase III, Randomized Trial of Reduced Intensity(RIC)
More informationImproved prognosis for acquired aplastic anaemia
158 Department of Haematology and Oncology, Great Ormond Street Hospital for Children NHS Trust, London WC1N 3JH, UK L A Pitcher I M Hann JPMEvans P Veys J M Chessells DKHWebb Correspondence to: Dr Webb.
More informationBiol Blood Marrow Transplant 19 (2013) 255e259
Biol Blood Marrow Transplant 19 (2013) 255e259 Transplantation Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Children and Adolescents with Acute Lymphoblastic
More informationHaploidentical Transplants for Lymphoma. Andrea Bacigalupo Universita Cattolica Policlinico Gemelli Roma - Italy
Haploidentical Transplants for Lymphoma Andrea Bacigalupo Universita Cattolica Policlinico Gemelli Roma - Italy HODGKIN NON HODGKIN Non Myelo Ablative Regimen Luznik L et al BBMT 2008 Comparison of Outcomes
More informationHee-Je Kim, Woo-Sung Min, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Chang-Ki Min, Seok Lee, Seok-Goo Cho, Jong-Youl Jin, Jong-Wook Lee, Chun-Choo Kim
Successful Prevention of Acute Graft-versus-Host Disease Using Low-Dose Antithymocyte Globulin after Mismatched, Unrelated, Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia Hee-Je
More informationClinical Policy Bulletin: Hematopoietic Cell Transplantation for Selected Leukemias
Go Clinical Policy Bulletin: Hematopoietic Cell Transplantation for Selected Leukemias Number: 0640 Policy *Please see amendment for Pennsylvania Medicaid at the end of this CPB. Additional Information
More informationInduction Therapy & Stem Cell Transplantation for Myeloma
Induction Therapy & Stem Cell Transplantation for Myeloma William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director, Autologous Stem Cell Transplant
More informationThe National Marrow Donor Program. Graft Sources for Hematopoietic Cell Transplantation. Simon Bostic, URD Transplant Recipient
1988 199 1992 1994 1996 1998 2 22 24 26 28 21 212 214 216 218 Adult Donors Cord Blood Units The National Donor Program Graft Sources for Hematopoietic Cell Transplantation Dennis L. Confer, MD Chief Medical
More informationOne Day BMT Course by Thai Society of Hematology. Management of Graft Failure and Relapsed Diseases
One Day BMT Course by Thai Society of Hematology Management of Graft Failure and Relapsed Diseases Piya Rujkijyanont, MD Division of Hematology-Oncology Department of Pediatrics Phramongkutklao Hospital
More informationTherapeutic Advances in Treatment of Aplastic Anemia. Seiji Kojima MD. PhD.
Therapeutic Advances in Treatment of Aplastic Anemia Seiji Kojima MD. PhD. Department of Pediatrics Nagoya University Graduate School of Medicine Chairman of the Severe Aplastic Anemia Working Party Asia-Pacific
More informationClinical Study Steroid-Refractory Acute GVHD: Predictors and Outcomes
Advances in Hematology Volume 2011, Article ID 601953, 8 pages doi:10.1155/2011/601953 Clinical Study Steroid-Refractory Acute GVHD: Predictors and Outcomes Jason R. Westin, 1 Rima M. Saliba, 1 Marcos
More informationClinical Policy: Donor Lymphocyte Infusion
Clinical Policy: Reference Number: PA.CP.MP.101 Effective Date: 01/18 Last Review Date: 11/16 Coding Implications Revision Log This policy describes the medical necessity requirements for a donor lymphocyte
More informationLow-Dose Total Body Irradiation, Fludarabine, and Antithymocyte Globulin Conditioning for Nonmyeloablative Allogeneic Transplantation
Biology of Blood and Marrow Transplantation 9:453-459 (2003) 2003 American Society for Blood and Marrow Transplantation 1083-8791/03/0907-0005$30.00/0 doi:10.1016/s1083-8791(03)00139-3 Low-Dose Total Body
More informationThe New England Journal of Medicine BONE MARROW TRANSPLANTS FROM UNRELATED DONORS FOR PATIENTS WITH CHRONIC MYELOID LEUKEMIA
BONE MARROW TRANSPLANTS FROM UNRELATED DONORS FOR PATIENTS WITH CHRONIC MYELOID LEUKEMIA JOHN A. HANSEN, M.D., THEODORE A. GOOLEY, PH.D., PAUL J. MARTIN, M.D., FREDERICK APPELBAUM, M.D., THOMAS R. CHAUNCEY,
More informationIN PHILADELPHIA CHROMOSOME positive (Ph )
Targeted Therapies in the Treatment of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Dieter Hoelzer, Nicola Gökbuget, and Oliver G. Ottmann Imatinib mesylate (Gleevec, Novartis Pharmaceuticals
More informationUnderstanding the role of ex vivo T cell depletion
Prevention of graftversus-host disease (GVHD) Understanding the role of ex vivo T cell depletion Information for patients undergoing allogeneic stem cell transplantation in AML and their families 2 This
More informationHematopoietic Stem Cells, Stem Cell Processing, and Transplantation
Hematopoietic Stem Cells, Stem Cell Processing, and Joseph (Yossi) Schwartz, M irector, Hemotherapy and Stem Cell Processing Facility Bone Marrow Can Cure: Leukemia Lymphoma Multiple Myeloma Genetic iseases:
More informationBusulfan/Cyclophosphamide (BuCy) versus Busulfan/Fludarabine (BuFlu) Conditioning Regimen Debate
Busulfan/Cyclophosphamide (BuCy) versus Busulfan/Fludarabine (BuFlu) Conditioning Regimen Debate Donald Hutcherson, RPh Clinical Pharmacy Specialist BMT Emory University Hospital/Winship Cancer Institute
More informationLondon, 27 October 2005 Product Name: Busilvex Procedure no.: EMEA/H/C/472/II/0004 SCIENTIFIC DISCUSSION
London, 27 October 2005 Product Name: Busilvex Procedure no.: EMEA/H/C/472/II/0004 SCIENTIFIC DISCUSSION 1 Introduction Busilvex contains the active substance busulfan in a concentrate for solution for
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Waldenstrom Macroglobulinemia File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem_cell_transplantation_for_waldenstrom_macroglobulinemia
More informationTiming and complications of allogeneic stem cell transplant in Ph + ALL
Timing and complications of allogeneic stem cell transplant in Ph + ALL Dr Ashlea Campbell Haematology Advanced Trainee Concord Repatriation and General Hospital Royal Prince Alfred Hospital 24 th Feb
More informationKEY WORDS: Unrelated SCT, HLA-mismatch, ATG, Graft-versus-host disease
HLA-Mismatched Unrelated Donors as an Alternative Graft Source for Allogeneic Stem Cell Transplantation after Antithymocyte Globulin-Containing Conditioning Regimen Nicolaus Kröger, 1 Tatjana Zabelina,
More informationAcknowledgements. Department of Hematological Malignancy and Cellular Therapy, University of Kansas Medical Center
The Addition of Extracorporeal Photopheresis (ECP) to Tacrolimus and Methotrexate to Prevent Acute and Chronic Graft- Versus Host Disease in Myeloablative Hematopoietic Cell Transplant (HCT) Anthony Accurso,
More informationPhiladelphia chromosome-positive acute lymphoblastic leukemia in childhood
Review article DOI: 10.3345/kjp.2011.54.3.106 Korean J Pediatr 2011;54(3):106-110 Philadelphia chromosome-positive acute lymphoblastic leukemia in childhood Hong Hoe Koo, M.D., Ph.D. Department of Pediatrics,
More informationHigh-Dose Carmustine, Etoposide, and Cyclophosphamide Followed by Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma
Biology of Blood and Marrow Transplantation 12:703-711 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1207-0002$32.00/0 doi:10.1016/j.bbmt.2006.02.009 High-Dose Carmustine,
More informationNeed considerable resources material and human.
TRAN VAN BINH INTRODUCTION Hematopoietic Stem cell transplantation: the best way to manage Malignancies and non Malignant blood disorders. Need considerable resources material and human. In developping
More informationWhat s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016
What s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016 Division of Hematology-Oncology University of Pennsylvania Perelman School of Medicine 1 Who should be transplanted and how? Updates
More informationTreatment of Chronic Graft versus Host Disease. Daniel Weisdorf MD University of Minnesota
Treatment of Chronic Graft versus Host Disease Daniel Weisdorf MD University of Minnesota October 2013 Infections Transplant Events d-8 0 1mo 3mo 6mo Conditioning Transplant Engraftment Mucositis Organ
More informationCuring Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham
Curing Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham What is cure after all? Getting rid of it? Stopping treatment without
More informationLong-Term Outcome of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Acute Myeloid Leukemia (AML)- Single Center Retrospective Analysis
Pathol. Oncol. Res. (2018) 24:469 475 DOI 10.1007/s12253-017-0266-7 ORIGINAL ARTICLE Long-Term Outcome of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Acute Myeloid Leukemia (AML)- Single
More informationHCT for Myelofibrosis
Allogeneic HSCT for MDS and Myelofibrosis Sunil Abhyankar, MD Professor Medicine, Medical Director, Pheresis and Cell Processing University of Kansas Hospital BMT Program April 27 th, 213 HCT for Myelofibrosis
More informationTransplantation with unrelated bone marrow in leukaemic patients above 40 years of age
Bone Marrow Transplantation, (1998) 21, 43 49 1998 Stockton Press All rights reserved 0268 3369/98 $12.00 Transplantation with unrelated bone marrow in leukaemic patients above 40 years of age O Ringdén
More informationLate effects after HSCT
Late effects after HSCT Yves Chalandon Hematology Division, University Hospital of Geneva (HUG) Switzerland Hôpitaux Universitaires de Genève Company name Disclosures of: Yves Chalandon Research support
More informationComparison of Reduced-Intensity and Conventional Myeloablative Regimens for Allogeneic Transplantation in Non-Hodgkin s Lymphoma
Biology of Blood and Marrow Transplantation 12:1326-1334 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1212-0001$32.00/0 doi:10.1016/j.bbmt.2006.08.035 Comparison of Reduced-Intensity
More informationStem Cell Transplantation
Stem Cell Transplantation Evelyne Willems Centre Hospitalier Universitaire, ULg, Liège Post-ASH meeting, January 11, 2012, Brussels Plan 1. Select the patient: validation of HCT-CI 2. Select the donor
More information